Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks prostate tumors on MRI after radiation

NCT ID NCT06822491

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to see how prostate tumors change on MRI scans shortly after a precise type of radiation therapy (SBRT). Researchers will compare these MRI changes with PSA levels in the blood. The study involves 28 men with localized prostate cancer and is designed to improve understanding of early treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients referred to our tertiary referral centre for prostate cancer

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with histologically confirmed localized prostate cancer who are planned for CT- or MRI-adaptive SBRT for prostate cancer; * Presence of PIRADS ≥3 lesion(s) in a mpMRI correlating with Gleason ≥7 score at diagnosis; * Intermediate to (very) high risk localized prostate cancer (≤ cT3b and cN0); * ECOG performance status of 0-2; * Age ≥ 18 years; * PSMA PET ≤3 months is compulsory for high-risk prostate cancer (as part of clinical routine); * Written informed consent. * Willingness and ability to comply with schedule Exclusion Criteria: * Previous (≤10 years) local therapy of the prostate including transurethral resection of the prostate (TURP), * Contraindication for MRI; * Previous (≤10 years) radiotherapy in the pelvis; * Lymph node metastases or distant metastases (i.e. no localized prostate cancer); * Participation in a clinical trial which might influence the results of this project; * Claustrophobic anxiety; * Uncontrolled intercurrent illness; * Relation to investigator (family or professional)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Localized prostate adenocarcinoma Magnetic resonance imaging Multiparametric mri Prostate carcinoma Stereotactic body radiotherapy Stereotactic radiotherapy

Contacts and locations

Locations

  • University Hospital Zurich

    Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.